Aptorum Group Faces Going Concern Warning Amidst Highly Dilutive DiamiR Reverse Merger and Internal Control Weakness

summarizeSummary

Aptorum Group's annual report reveals a going concern warning from its auditor and management, alongside a material weakness in internal financial controls, as it pursues a highly dilutive reverse merger with DiamiR Biosciences that will leave existing shareholders with only 30% ownership of the combined entity.

check_boxKey Events · M&A and Partnerships · APM

• Going Concern Warning Issued

  Both management and the independent auditor have expressed substantial doubt about Aptorum Group's ability to continue as a going concern due to recurring net losses of $1.38 million in 2025 and negative working capital of $1.00 million as of December 31, 2025.

• Highly Dilutive Reverse Merger with DiamiR Biosciences

  The company is proceeding with a reverse merger with DiamiR Biosciences, where DiamiR stockholders will own approximately 70% and existing Aptorum shareholders will own 30% of the combined company. This transaction is subject to several closing conditions, including Aptorum maintaining specific cash and working capital levels, which were not met as of December 31, 2025.

• Material Weakness in Internal Controls

  Management identified a material weakness in internal control over financial reporting for the year ended December 31, 2025, attributed to a lack of dedicated resources for finance and accounting functions.

• Significant Capital Raises in 2025

  Aptorum Group completed two registered direct offerings in January and October 2025, raising aggregate gross proceeds of $5.07 million. The October 2025 offering included 2,000,000 restricted warrants, and both offerings were priced at $2.00 per share, significantly above the current stock price of $0.93.

auto_awesomeAnalysis · APM · Industrial Applications And Services

Aptorum Group's annual report for 2025 highlights severe financial and operational challenges. Both management and the independent auditor have expressed substantial doubt about the company's ability to continue as a going concern, citing recurring net losses and negative working capital. The company is pursuing a reverse merger with DiamiR Biosciences, a transaction that will result in significant dilution for existing Aptorum shareholders, who are projected to own only 30% of the combined entity. This strategic pivot, which caused a pause in R&D activities, is critical for the company's future but comes with substantial risks, including unmet cash and working capital conditions. Additionally, a material weakness in internal financial reporting controls was identified, further raising governance concerns. These factors collectively present a highly negative outlook for investors.